2023-504304-29-00CompletedPhase 1
A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Selnoflast in Participants with Moderate to Severe Asthma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 Sept 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 21 Sept 2023
- Start date
- 1 Mar 2024
- Lead sponsor
- F. Hoffmann-La Roche AG
- Diseases
- Asthma
- EU CT number
- 2023-504304-29-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 30
- 7 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Liège | Liège | Belgium | Completed |
| Velocity Clinical Research Germany GmbH | Ahrensburg | Germany | Completed |
| Parexel International GmbH | Berlin | Germany | Completed |
| IKF Pneumologie GmbH & Co. KG | Frankfurt am Main | Germany | Completed |
| Velocity Clinical Research Germany GmbH | Luebeck | Germany | Completed |
| IKF Pneumologie GmbH & Co. KG | Mainz | Germany | Completed |
| Universitair Medisch Centrum Groningen | Groningen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.